EquityIndex FundsVery High Risk
Direct
NAV (12-May-25)
Returns (Since Inception)
Fund Size
₹135 Cr
Expense Ratio
0.50%
ISIN
INF277KA1BG3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
26 Apr 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+20.86%
— (Cat Avg.)
Since Inception
+19.10%
— (Cat Avg.)
Equity | ₹134.72 Cr | 99.99% |
Others | ₹0.02 Cr | 0.01% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹20.01 Cr | 14.85% |
Lupin Ltd | Equity | ₹12.41 Cr | 9.21% |
Fortis Healthcare Ltd | Equity | ₹8.76 Cr | 6.50% |
Aurobindo Pharma Ltd | Equity | ₹8.43 Cr | 6.25% |
Mankind Pharma Ltd | Equity | ₹6.82 Cr | 5.06% |
Alkem Laboratories Ltd | Equity | ₹6.67 Cr | 4.95% |
Laurus Labs Ltd | Equity | ₹5.79 Cr | 4.30% |
Glenmark Pharmaceuticals Ltd | Equity | ₹5.1 Cr | 3.78% |
Ipca Laboratories Ltd | Equity | ₹4.77 Cr | 3.54% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹3.95 Cr | 2.93% |
Abbott India Ltd | Equity | ₹3.83 Cr | 2.84% |
Biocon Ltd | Equity | ₹3.55 Cr | 2.64% |
Suven Pharmaceuticals Ltd | Equity | ₹3.54 Cr | 2.63% |
Piramal Pharma Ltd | Equity | ₹3.19 Cr | 2.37% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹3.01 Cr | 2.23% |
Syngene International Ltd | Equity | ₹2.94 Cr | 2.18% |
Narayana Hrudayalaya Ltd | Equity | ₹2.93 Cr | 2.18% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹2.84 Cr | 2.10% |
Ajanta Pharma Ltd | Equity | ₹2.79 Cr | 2.07% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹2.79 Cr | 2.07% |
Gland Pharma Ltd | Equity | ₹2.73 Cr | 2.03% |
Dr. Lal PathLabs Ltd | Equity | ₹2.53 Cr | 1.88% |
Neuland Laboratories Ltd | Equity | ₹2.52 Cr | 1.87% |
Global Health Ltd | Equity | ₹2.44 Cr | 1.81% |
Poly Medicure Ltd | Equity | ₹2.41 Cr | 1.79% |
Natco Pharma Ltd | Equity | ₹1.87 Cr | 1.39% |
Rainbow Childrens Medicare Ltd | Equity | ₹1.69 Cr | 1.26% |
Granules India Ltd | Equity | ₹1.62 Cr | 1.20% |
Pfizer Ltd | Equity | ₹1.6 Cr | 1.18% |
Alembic Pharmaceuticals Ltd | Equity | ₹1.2 Cr | 0.89% |
A) Repo | Cash - Repurchase Agreement | ₹0.03 Cr | 0.02% |
Net Current Liabilities | Cash - Collateral | ₹-0.01 Cr | 0.01% |
Large Cap Stocks
--
Mid Cap Stocks
66.12%
Small Cap Stocks
33.87%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹134.72 Cr | 99.99% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since April 2024
Since December 2024
ISIN INF277KA1BG3 | Expense Ratio 0.50% | Exit Load No Charges | Fund Size ₹135 Cr | Age 1 year | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty MidSmall Healthcare Index (TRI) |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Your principal amount will be at Very High Risk
EquityIndex FundsVery High Risk
Direct
NAV (12-May-25)
Returns (Since Inception)
Fund Size
₹135 Cr
Expense Ratio
0.50%
ISIN
INF277KA1BG3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
26 Apr 2024
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+20.86%
— (Cat Avg.)
Since Inception
+19.10%
— (Cat Avg.)
Equity | ₹134.72 Cr | 99.99% |
Others | ₹0.02 Cr | 0.01% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹20.01 Cr | 14.85% |
Lupin Ltd | Equity | ₹12.41 Cr | 9.21% |
Fortis Healthcare Ltd | Equity | ₹8.76 Cr | 6.50% |
Aurobindo Pharma Ltd | Equity | ₹8.43 Cr | 6.25% |
Mankind Pharma Ltd | Equity | ₹6.82 Cr | 5.06% |
Alkem Laboratories Ltd | Equity | ₹6.67 Cr | 4.95% |
Laurus Labs Ltd | Equity | ₹5.79 Cr | 4.30% |
Glenmark Pharmaceuticals Ltd | Equity | ₹5.1 Cr | 3.78% |
Ipca Laboratories Ltd | Equity | ₹4.77 Cr | 3.54% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹3.95 Cr | 2.93% |
Abbott India Ltd | Equity | ₹3.83 Cr | 2.84% |
Biocon Ltd | Equity | ₹3.55 Cr | 2.64% |
Suven Pharmaceuticals Ltd | Equity | ₹3.54 Cr | 2.63% |
Piramal Pharma Ltd | Equity | ₹3.19 Cr | 2.37% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹3.01 Cr | 2.23% |
Syngene International Ltd | Equity | ₹2.94 Cr | 2.18% |
Narayana Hrudayalaya Ltd | Equity | ₹2.93 Cr | 2.18% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹2.84 Cr | 2.10% |
Ajanta Pharma Ltd | Equity | ₹2.79 Cr | 2.07% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹2.79 Cr | 2.07% |
Gland Pharma Ltd | Equity | ₹2.73 Cr | 2.03% |
Dr. Lal PathLabs Ltd | Equity | ₹2.53 Cr | 1.88% |
Neuland Laboratories Ltd | Equity | ₹2.52 Cr | 1.87% |
Global Health Ltd | Equity | ₹2.44 Cr | 1.81% |
Poly Medicure Ltd | Equity | ₹2.41 Cr | 1.79% |
Natco Pharma Ltd | Equity | ₹1.87 Cr | 1.39% |
Rainbow Childrens Medicare Ltd | Equity | ₹1.69 Cr | 1.26% |
Granules India Ltd | Equity | ₹1.62 Cr | 1.20% |
Pfizer Ltd | Equity | ₹1.6 Cr | 1.18% |
Alembic Pharmaceuticals Ltd | Equity | ₹1.2 Cr | 0.89% |
A) Repo | Cash - Repurchase Agreement | ₹0.03 Cr | 0.02% |
Net Current Liabilities | Cash - Collateral | ₹-0.01 Cr | 0.01% |
Large Cap Stocks
--
Mid Cap Stocks
66.12%
Small Cap Stocks
33.87%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹134.72 Cr | 99.99% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since April 2024
Since December 2024
ISIN INF277KA1BG3 | Expense Ratio 0.50% | Exit Load No Charges | Fund Size ₹135 Cr | Age 1 year | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty MidSmall Healthcare Index (TRI) |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments